Among those, olaparib was firstly approved as the maintenance therapy in 2014, particularly for platinum-sensitive advanced ovarian cancer with germline mutations in BRCA1/2 genes that are involved in the HR pathway of DNA double-strand break (DSB) repair. This evidence concerns the gene BRCA1 and ovarian cancer.